Clinomics Inc. (352770)

Overview

Clinomics Inc. is at the forefront of the biotechnology sector, focusing on providing genome-based diagnostic solutions for cancer and other diseases. Since its founding in 2011 and based in Ulsan, South Korea, Clinomics has been dedicated to leveraging advanced genomic data for healthcare advancements. The company integrates cutting-edge technologies in RT-PCR tests for COVID-19, liquid biopsy, precision medicines, healthcare services, and big data analytics to address the pressing needs of modern medical diagnostics and treatment guidance. Through its innovative approaches, Clinomics aims to revolutionize personalized medicine and enhance patient care by enabling more precise diagnosis and targeted treatment options.

Products and Services

TrioDx RT-PCR COVID-19 Test (FDA EUA): A test provided by Clinomics to detect COVID-19, authorized under Emergency Use Authorization (EUA) by the FDA, ensuring reliable results for critical diagnostics.

Liquid Biopsy and Precision Medicines: Clinomics offers a range of solutions in this category, including:

• CD-PRIME: An automated platform for the enrichment of circulating tumor cells (CTCs), cell-free DNA, and EV (exosome) derived from cancer tissues, facilitating the early detection and treatment of cancer.
• Cancer-PRIME: A service for cancer gene analysis that integrates bioinformatics for precision medicine, focusing on the detection of gene mutations that are crucial for personalized treatment approaches.
• BioViewCCBS: A scanning platform designed for the 3D capture and analysis of cells within a sample, particularly for identifying and analyzing circulating tumor cells.

Distributor and Seller: Clinomics also serves as a distributor and seller in Korea for several diagnostics and analysis kits and systems, including:

• AmoyDx's molecule diagnosis method kits: Used to predict NSCLC (Non-Small Cell Lung Cancer) patients' reactions to specific drug treatments.
• Fluxion Biosciences' Spotlight 59 Panel: Offers sensitive detection of mutated cells in cancer samples, aiding in the precise identification of tumor mutations.
• Fluxion Biosciences' IsoFlux System: An analysis system for circulating tumor cells, enabling the extraction of rare cells for further study and application in various fields.

Healthcare Services: Clinomics provides a suite of services, each focusing on different aspects of genomic and health analysis, including:

• Geno-P: Offers specialized genome information for predicting physical characteristics, based on genomic reference data.
• Geno-D: A service for the prediction of disease incidence probability, aiding in proactive health management.
• GenomeBook: Provides comprehensive whole genome information, offering insights into an individual’s genetic makeup.
• NIP10: A non-invasive prenatal testing service available after 10 weeks of pregnancy, for the detection of fetal chromosome abnormalities.
• Biological Age Analysis Service: Analyzes an individual's biological age, offering insights into health and longevity.

BioComputer: An automated computing infrastructure designed by Clinomics to process genomic data efficiently, supporting the growing need for big data analysis in genomics.